Claims for Patent: 6,689,761
✉ Email this page to a colleague
Summary for Patent: 6,689,761
| Title: | Combination therapy for HIV infection |
| Abstract: | The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. |
| Inventor(s): | Chodakewitz; Jeffrey A. (Gwynedd Valley, PA), Emini; Emilio A. (Paoli, PA) |
| Assignee: | Merck & Co., Inc. (Rahway, NJ) |
| Application Number: | 08/382,113 |
| Patent Claims: |
1. A combination of compounds, which is Compound J, nucleoside analog HIV reverse transcriptase inhibitor 3TC, and nucleoside HIV reverse transcriptase inhibitor AZT, or a
pharmaceutically acceptable salt or ester thereof.
2. The method of claim 1, wherein the combination is administered simultaneously. 3. The method of claim 1, wherein the combination is administered alternatively. 4. A method of inhibiting HIV protease, comprising administering to a suitable mammal in need of such treatment an effective amount of the combination of claim 1. 5. A method of inhibiting HIV reverse transcriptase, comprising administering to a suitable mammal in need of such treatment an effective amount of the combination of claim 1. 6. A method of treating infection by HIV, AIDS or ARC, comprising administering to a suitable mammal in need of such treatment an effective amount of the combination of claim 1. 7. A pharmaceutical composition useful for inhibiting HIV protease, comprising an effective amount of the combination of claim 1, and a pharmaceutically acceptable carrier. 8. A pharmaceutical composition useful for inhibiting HIV reverse transcriptase, comprising an effective amount of the combination of claim 1, and a pharmaceutically acceptable carrier. 9. A pharmaceutical composition useful for treating infection of HIV, or for treating AIDS or ARC, comprising an effective amount of the combination of claim 1, and a pharmaceutically acceptable carrier. |
